

CURRICULUM VITAE

First name	Francesco
Surname	Bertoni
Date of birth	August 5th, 1969
Place of birth	Rome, Italy
Citizenship	Italian
Marital status	Married, two daughters
Work address	Lymphoma Genomics Group, head IOR - Institute of Oncology Research, deputy director, Universita' della Svizzera italiana via Vincenzo Vela 6, 6500 Bellinzona Switzerland
phone	+41 91 820 0367
E-mail	frbertoni@mac.com
ORCID	https://orcid.org/0000-0001-5637-8983
Link to updated and full publications list	https://www.dropbox.com/s/4mvdfunv5kkcau6/pubs.pdf?dl=0

EDUCATIONAL BACKGROUND

July 26th, 1994 Medical Doctor, State University of Milan, Italy

SPECIALITY BOARD

November 10th, 1998 Post-graduated in Oncology, Specialty School of Oncology, State University of Milan, Italy

OTHER EDUCATION

June, 2015 FELASA Category B LTK module 1, University of Zurich, Zurich, Switzerland

RESEARCH TOPICS

Development of new anti-lymphoma compounds

Lymphoma genomics

WORKING EXPERIENCES

Since March 2003	IOR - Institute of Oncology Research (former "Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (IOSI)", up to 9-2011), Bellinzona, Switzerland
October 1999 – February 2003	Department of Experimental Haematology (Finbarr E. Cotter), The Barts and The London - Queen Mary's School of Medicine and Dentistry, London, UK
April- September 1999	Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (Franco Cavalli), c/o Ospedale Regionale, Locarno, Switzerland
April 1998 – March 1999	Molecular Pharmacology Unit (Massimo Broggin), Department of Oncology (Maurizio D'Incalci), "Mario Negri" Institute of Pharmacological Research, Milan, Italy
Jan. - mid April 1998	Molecular Haematology Unit (Finbarr E. Cotter), Institute of Child Health, University College London Medical School, London, United Kingdom
Jan. 1996 - Dec. 1997	Medical Oncology Department and Bone Marrow Transplantation Laboratory (Emanuele Zucca), Servizio Oncologico Cantonale (Franco Cavalli), Ospedale Regionale, Locarno, Switzerland

Aug. 1995	Medical Oncology Department, Servizio Oncologico Cantonale (Franco Cavalli), Ospedale San Giovanni, Bellinzona, Switzerland
Feb. - Dec. 1995	Service of Medical Oncology (Paolo Foa) at the Ist Postgraduate School of Haematology (Anna Teresa Maiolo), State University, Ospedale Maggiore, Milan, Italy
Nov. 1991 - Jan. 1995	Division of Medicine II (Claudio Rugarli), Istituto Scientifico San Raffaele, Milan, Italy

MEMBERSHIPS

American Association for Cancer Research (AACR); American Society of Hematology (ASH); British Society of Haematology (BSH), European Society for Medical Oncology (ESMO); European Hematology Association (EHA); European Association for Cancer Research (EACR); British Society of Haematology (BSH); Società Italiana di Cancerologia (SIC); European Association for Cancer Research (EACR); Associazione Italiana di Oncologia Medica (AIOM); International Extranodal Lymphoma Study Group (IELSG); Swiss Group for Clinical Cancer Research (SAKK); NCCR RNA & Disease; The European T-Cell Lymphoma Study Group.

HONORS AND FELLOWSHIPS

Since Feb. 2019	Adjunct Professor at Università della Svizzera italiana (USI)
July 2017-July 2023	Italian "Abilitazione Scientifica Nazionale alle funzioni di Professore Universitario di Prima Fascia", Bando D.D. 1532/2016, Settore Concorsuale 06/D3 "Malattie del Sangue, Oncologia e Reumatologia"
Since June 2016	Vice-president of the Project Group Lymphoma of the Swiss Group for Clinical Cancer Research (SAKK)
Since May 2012	authorized Thesis Director, UNIL Université de Lausanne, Lausanne, Switzerland
Since Sept 2011	Head of the Lymphoma and Genomics Research Program, and Deputy Director of the Institute of Oncology Research, Bellinzona, Switzerland
Apr 2007- Sept 2011	Deputy Director of Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland
Mar 2003- Sept 2011	Head of the Functional Genomics, Lymphoma Unit, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland
1998	Degree in Oncology summa cum laude, with degree thesis " <i>Analisi molecolare del riarrangiamento genico delle catene pesanti delle immunoglobuline nel linfoma primitivo gastrico a cellule B della zona marginale (di tipo MALT)</i> " (Milan, November 10 th , 1998)
1994	Graduated summa cum laude, with degree thesis " <i>Linfomi non Hodgkin a grado intermedio-alto di malignità: strategie terapeutiche ed esperienza presso l'Istituto San Raffaele</i> " (State University of Milan, Milan, July 26 th , 1994)

Since 1-2008, Editor-in-Chief of Hematological Oncology. Since 6-2007, Member of the Editorial Board of Leukemia and Lymphoma. Since 2-2005 to 12-2007, Associate Editor of Hematological Oncology. Since Dec. 2013 Member of the Editorial Board of Cancer Biology & Medicine. Since 2013 to 2014, Lymphoma co-Editor of the Elsevier Ltd website "Leukaemia & Lymphoma".

Reviewer of manuscripts and books for *American Journal of Pathology*, *Annals of Oncology*, *Blood*, *BMC Cancer*, *British Journal of Haematology*, *Cancer*, *Cancer Discovery*, *Clinical Cancer Research*, *Clinical Lymphoma*, *European Journal of Cancer*, *International Journal of Cancer*, *Journal of Pathology*, *Journal of Clinical Pathology*, *Lancet*, *Lancet Haematology*, *Leukemia*, *Leukemia and Lymphoma*, *Veterinary and Comparative Oncology*. Reviewer of national and international grant applications, and of abstracts submitted to international conferences.

PATENTS

Gaudio E, Bertoni F, Pazzi N, Guala M. New compounds with enhanced anti-tumor effects. PCT/EP2018/057678. Filing date: March 26th 2018. Applicant: Fondazione Per L'istituto Oncologico Di Ricerca (IOR).

Marques CS, Busto N, Gaudio E, Bertoni F, Burke AJ. Novel N-(1,2,3-Triazolmethyl)Isatin and N-(1,2,3-Triazolmethyl)-3-Hydroxy-3-aryloxindoles with Cytotoxic and Anti-Tumor Activity. PTA 11006317. Filing date: 2018-04-18. Original Assignee: Universidad de Evora.

Bertoni F, Romanelli A, Sloss C. Methods for improving anti-cd37 immunoconjugate therapy. PCT/IB2017/056841. WO2018083633A1. Priority date: 2016-11-02. Original Assignee: Debiopharm International, S.A.

Riveiro ME, Raymond E, Bertoni F. Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds. WO2015189814 A1. Priority date: 2014-06-13. Publication date: 2015-12-17. Original Assignee: ONCOETHIX GmbH.

Bertoni F, Inghirami G. Method of treating diffuse large B-cell lymphoma (DLBCL) using a BET-bromodomain inhibitor. PCT/EP2014/002164, WO2015018521 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.

Bertoni F, Inghirami G. A BET-BRD inhibitor represents a novel agent for ALK positive anaplastic large cell lymphoma. WO2015018520 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.

Bertoni F, Inghirami G. Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large B-cell lymphoma (DLBCL). PCT/EP2014/002163, WO2015018522 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.

Bertoni F, Bonetti P. Method of treating lymphoma using thienotriazolodiazepine compounds. PCT/EP2013/063313, WO2014001356 A1. Priority date: 2012-06-25. Publication date: 2015-04-29. Original Assignee: Oncoethix Sa.

Bertoni F. Method of treating lymphoma using thienotriazolodiazepine compounds. PCT/EP2015/069092, US15504722. Priority date: 2014-08-19. Publication date: 2015-08-19. Original Assignee: Original Assignee: ONCOETHIX GmbH.

Bertoni F, Noel K. Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds. PCT/US2015/028835, WO2015168587 A1. Priority date: 2014-05-02. Publication date: Nov 5, 2015. Original Assignee: Oncoethix Sa.

Simon G, Giannella-Borradori A, & Bertoni F. Roscovitine treatment of mantle cell lymphoma. PCT/GB2004/004700, WO2005044274 A1. Priority date: 2003-11-06. Publication date: 2005-05-19. Original Assignee: Cyclacel Limited.

THESIS SUPERVISION

- PhD thesis, "Preclinical evaluation of the ETS inhibitors YK-4-279 and TK-216 in lymphoma" by Filippo Spriano, UNIL, Lausanne, Switzerland (on-going)
- PhD thesis, "Role of ETS1 in the biology of ABC DLBCL" by Valdemar Priebe, UNIL, Lausanne, Switzerland (2018)
- PhD thesis, "Epigenome as a therapeutic target for lymphomas" by Elena Bernasconi, UNIL, Lausanne, Switzerland (2017)
- PhD thesis, "The contribution of genomic aberration to the pathogenesis of mature B-cell lymphomas" by Monica Testoni, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, 2014
- PhD thesis, "Anaplastic large cell lymphoma: one or more entities?" by Michela Boi, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, 2013
- PhD thesis, "Genomic profiling of diffuse large B-cell lymphomas" by Marta Scandurra, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, 2010
- PhD thesis, "Stochastic methods in cancer research. Applications to genomics and angiogenesis" by Paola Rancoita, Universita' degli Studi di Milano, Dipartimento di Matematica, Milan, Italy
- PhD thesis, "Genomic profiling of B-cell lymphoid neoplasms" by Giulia Poretti, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, 2009

LAST MAIN GRANTS

Title	Grant #	start	end	Amount given	
An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma	Oncosuisse KFS-4727-02-2019	08-2019	07-2022	CHF 360,305	main applicant
Finding a way to by-pass the resistance to PI3K inhibitors in marginal zone lymphomas	Fondazione Ticinese per la Ricerca sul Cancro	06-2019	05-2020	CHF 60,000	main applicant
Novel small molecule targets FLI1 in lymphoma and T-ALL	Leukemia & Lymphoma Society #6521-17	10-2016	09-2019	USD 600,000	main applicant
Targeted agents in splenic marginal zone lymphoma: mechanisms of resistance and new combinations	SNSF 31003A_163232/1	10-2015	09-2018	CHF 429,800	main applicant
Characterization of FLI1 as an oncogene and therapeutic target in diffuse large B-cell lymphomas	Oncosuisse KLS-3580-02-2015	08-2015	07-2018	CHF 359,800	main applicant

LIST OF PUBLICATIONS OF THE LAST FIVE YEARS

(full list at : <https://www.dropbox.com/s/4mvdvfunv5kkcau6/pubs.pdf?dl=0>)

A) ORIGINAL PAPERS

1. Spriano F[^], Chung EYL[^], Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretsky JA, Bertoni F. The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents. **Clinical Cancer Research** 2019 Jun 10. pii: clincanres.2718.2018. doi: 10.1158/1078-0432.CCR-18-2718. [Epub ahead of print] ([^], equally contributed).
2. Hicks SW[^], Tarantelli C[^], Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Pittau Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stussi G, Zucca E, Stathis A, Sloss CM*, Bertoni F*. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models. **Haematologica** 2019 Feb 7. pii: haematol.2018.211011. doi: 10.3324/haematol.2018.211011. [Epub ahead of print]. ([^], equally contributed; *, co-senior authors).
3. Ferrero S[^] Rossi D[^], Rinaldi A[^], Bruscazzin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomes da Silva M, Santoro A, Molinari A, Ferreri A, Grønbaek K, Piccin A, Cortelazzo S, Bertoni F*, Ladetto M*, Gaidano G*. *KMT2D* mutations and *TP53* disruptions are poor prognostic biomarkers in MCL receiving high-dose therapy: a FIL study. **Haematologica** 2019: in press ([^], equally contributed)(, co-senior authors).
4. Spriano F[^], Tarantelli C[^], Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, Stathis A, Zucca E, Bertoni F. Single and combined BTK and PI3K δ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. **British Journal of Haematology** 2019: in press. ([^], equally contributed).
5. Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L, Cascione L, Rageot D, Kwee I, Beauflis F, Zucca E, Stathis A, Wymann MP, Cmiljanovic V, Fabbro D, Bertoni F. The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as single agent and in combination of venetoclax. **Cancers (Basel)** 2019 Jun 4;11(6). pii: E775. doi: 10.3390/cancers11060775.
6. Arribas AJ[^], Rinaldi A[^], Chiodin G, Kwee I, Mensah AA, Cascione L, Rossi D, Kanduri M, Rosenquist R, Zucca E, Johnson PW, Gaidano G, Oakes CO, Bertoni F*, Forconi F*. Genome-wide promoter methylation of hairy cell leukemia. **Blood Advances** 2019 Feb 12;3(3):384-396. doi: 10.1182/bloodadvances.2018024059. ([^], equally contributed; *, co-senior authors).
7. Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, Stathis A, Bertoni F. The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. **Haematologica** 2019 Jul; 104(7): e307–e309.
8. Cascione L[^], Rinaldi A[^], Bruscazzin A, Tarantelli C, Arribas A, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, Terzi di Bergamo L, Dirnhofer S, Tzankov A, Miranda R, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow S, Gascoyne RD, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. **Haematologica** 2019 Apr 24. pii: haematol.2018.214957. doi: 10.3324/haematol.2018.214957. [Epub ahead of print]. ([^], equally contributed; *, co-senior authors).
9. Laginestra MA[^], Cascione L[^], Motta G, Fuligni F, Agostinelli C, Rossi M, Sapienza MR¹, Righi S, Broccoli A, Indio V, Melle F, Tabanelli V, Calleri A, Novero D, Facchetti F, Inghirami G, Sabattini E, Bertoni F, Pileri SA[^]. Whole exome sequencing reveals mutations in *FAT1* tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. **Modern Pathology** 2019 Apr 25. doi: 10.1038/s41379-019-0279-8. [Epub ahead of print] ([^], equally contributed)(, co-senior authors).
10. Tarantelli C, Gaudio E, Cascione L, Stathis A, Zucca E, Bertoni F. In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. **British Journal of Haematology** 2019; 186(1): 149-152.
11. Mondello P, Cuzzocrea S, Arrigo C, Pitini V, Mian M*, Bertoni F. STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in Primary Central Nervous System Lymphoma. **Hematological Oncology** 2019 Sep 16. doi: 10.1002/hon.2679. [Epub ahead of print] (, co-senior authors).
12. Astorgues-Xerri L[^], Vázquez R[^], Odore E, Rezai K, Kahatt C, MacKenzie S, Bekradda M, Coudé MM, Dombret H, Gardin C, Lokiec F, Raymond E, Noel K, Cvitkovic E, Herait P, Bertoni F*, Riveiro ME*. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. **Leukemia and Lymphoma** 2019: in press ([^], equally contributed; *, co-senior authors).
13. Cascione L[^], Giudice L[^], Ferraresso S, Marconato L, Giannuzzi D, Napoli S, Bertoni F*, Giugno R*, Aresu L*. Long non-coding RNAs as molecular signature to canine B-cell lymphoma characterization. **Non-Coding RNA** 2019: in press ([^], equally contributed; *, co-senior authors).
14. Fallacara AL, Passannanti R, Moria M, Iovenitti G, Musumeci F, Greco C, Crespan E, Kissova M, Iovanni Maga G, Tarantelli C, Spriano F, Gaudio E, Bertoni F, Botta M, Schenone S. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Btk-Lyn inhibitors active on B- and T-lymphoma cell lines. **European Journal of Medicinal Chemistry** 2019: in press (<https://doi.org/10.1016/j.ejmech.2019.07.048>).
15. Restelli V[^], Lupi M[^], Chila' R, Vagni M, Tarantelli C, Spriano F, Gaudio E, Bertoni F, Damia G*, & Carrassa L*. DNA damage response inhibitor combinations exert synergistic antitumor activity in aggressive B cell lymphomas. **Molecular Cancer Therapeutics** 2019: in press. ([^], equally contributed; *, co-senior authors).
16. Heavican TB[^], Bouska A[^], Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismä gi M-L, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Massiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J. Genetic Drivers of Oncogenic Pathways in Molecular Subgroups of Peripheral T-Cell Lymphoma. **Blood** 2019 Apr 11;133(15):1664-1676. ([^], equally contributed).

17. Cascione L[^], Pontali G[^], Arribas AJ, Rinaldi A, Bertoni F, Giugno R. A reliable method to remove batch effects maintaining group differences in lymphoma methylation case study. **Lecture Notes in Bioinformatics** 2019, *in press* (^, equally contributed).
18. Sasi BK, Turkalj S, Kalkan H, Bojnik E, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, and Efremov DG. Inhibition of SYK or BTK overcomes venetoclax resistance in SHP1 negative/BCL-2 positive diffuse large B-cell lymphoma. **Leukemia** 2019 Mar 14. doi: 10.1038/s41375-019-0442-8. [Epub ahead of print].
19. Diop F[^], Moia R[^], Favini C, Spaccarotella E, De Paoli L, Brusca A, Spina V, -di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foà R, Gaidano G* and Rossi D*. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. **Haematologica** August 2019: haematol.2019.219550; Doi:10.3324/haematol.2019.219550 (^, equally contributed). (*, co-senior authors).
20. Giannuzzi D, Marconato L, Cascione L, Comazzi S, Elgandy R, Pegolo S, Cecchinato A, Bertoni F, Aresu L*, Ferraresso S*. Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq. **PLOS ONE** 2019 Apr 24;14(4):e0215154. doi: 10.1371/journal.pone.0215154. eCollection 2019. (*, co-senior authors).
21. González-Rincón J, Méndez M, Gómez S1, García JF, Martín P, Bellas C, Rodríguez-Pinilla SM, Camacho FI, Quero C, Pérez-Callejo D, Rueda A, Llanos M, Gómez-Codina J, Piris MA, Montes-Moreno S2,12, Bárcena C, Rodríguez-Abreu D, Menárguez J, de la Cruz-Merino L, Monsalvo S, Pedrosa L1, Parejo C, Royuela A, Kwee I, Cascione L, Alberto Arribas A, Bertoni F, Mollejo M, Provencio M[^], Margarita Sánchez-Beato M[^]. Unravelling transformation of follicular lymphoma to diffuse large B-cell lymphoma. **PLOS One** 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019. (^, co-senior authors).
22. Aresu L, Ferraresso S, Marconato L, Cascione L, Napoli S, Gaudio E, Kwee I, Tarantelli C, Testa A, Maniaci C, Ciulli A, Hillmann P, Bohnacker T, Wymann MP, Comazzi S, Milan M, Riondato F, Dalla Rovere G, Giantin M, Giannuzzi D, Bertoni F. New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease. **Haematologica** 2018 Dec 13. pii: haematol.2018.207027. doi: 10.3324/haematol.2018.207027. [Epub ahead of print] (*, co-senior authors).
23. Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen S-S, Chiorazzi N, Thompson P, Ferrajoli A, Bertoni F, Stilgenbauer S, J. Keating MJ, Calin GA. miRNAs involvement in the pathogenesis of Richter's syndrome. **Haematologica** 2018 Nov 8. pii: haematol.2018.203828. doi: 10.3324/haematol.2018.203828. [Epub ahead of print]
24. Tarantelli T*, Gaudio E*, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Bordone Pittau R, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Brogini M, Wymann MP, Wicki A, Zucca E, Cmijanovic V, Fabbro D, Bertoni F. PQR309 is a novel dual PI3K/mTOR inhibitor with pre-clinical antitumor activity in lymphomas as a single agent and in combination therapy. **Clinical Cancer Research**: 2018;24(1):120-129. (*, equally contributed)
25. Mensah AA*, Cascione L*, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F. Bromodomain and Extra-Terminal Domain Inhibition Modulates the Expression of Pathologically Relevant MicroRNAs in Diffuse Large B-Cell Lymphoma. **Haematologica** 2018; 103(12): 2049-2058. (*, equally contributed)
26. Tarantelli C*, Bernasconi E*, Gaudio E, Cascione L, Restelli V, Arribas A, Spriano F, Rinaldi A, Mensah AA, Kwee I, Ponzoni M, Zucca E, Carrassa L, Riveiro ME, Rezai K, Stathis A, Cvitkovic E, Bertoni F. The BET Bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. **ESMO Open** 2018 Sep 26;3(6):e000387 <http://dx.doi.org/10.1136/esmoopen-2018-000387>. (*, equally contributed).
27. Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F*, Bernasconi E* and the Swiss HIV Cohort study (SHCS). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. **Hematological Oncology** 2018 Dec;36(5):757-764. (*, co-senior authors).
28. Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omede' PM, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. **Blood** 2019 Jan 10;133(2):156-167.
29. Bonnici V, Busato F, Aldegheri S, Akhmedov M, Cascione L, Arribas Carmena A, Bertoni F, Bombieri N, Kwee I, Giugno R. cuRnet: an R package for graph traversing on GPU. **BMC Bioinformatics** 2018 Oct 15;19(Suppl 10):356. doi: 10.1186/s12859-018-2310-3.
30. Da Ros S., Aresu L, Ferraresso S, Zorzan E, Gaudio E, Bertoni F, Dacasto M, Giantin M. Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: an *in vitro* and *in vivo* approach. **PLOS One** 2018 Dec 11;13(12):e0208709. doi: 10.1371/journal.pone.0208709. eCollection 2018.
31. Spina S, Brusca A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaüs S, Carlo-Stella C, Rossi D. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. **Blood** 2018 May 31;131(22):2413-2425.
32. Gerber B*, Manzoni M*, Spina V, Brusca A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. **Haematologica** 2018 Jun;103(6):e245-e248. (*, equally contributed)
33. Chen J, Guccini I, Mitri DD, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. **Nature Genetics** 2018 Feb;50(2):219-228.
34. Bergmann TJ, Fregno I, Fumagalli F, Rinaldi A, Bertoni F, Boersema PJ, Picotti P, Molinari M. Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. **The Journal of Biological Chemistry** 2018 Apr 13;293(15):5600-5612. [Epub ahead of print].
35. Chung E*, Spriano F*, Panini N, Cascione L, Rinaldi A, Erba E, Stathis A, D'Incalci M, Bertoni F[^], Gatta R[^]. Trabectedin is

- a novel chemotherapy agent for diffuse large B cell lymphoma. **British Journal of Haematology** 2018 Apr 2. doi: 10.1111/bjh.15212. [Epub ahead of print]. (*, equally contributed; ^, co-senior authors)
36. Restelli V*, Vagni M*, Arribas A, Bertoni F, Damia G & Carrassa L. Inhibition of Chk1 and Wee1 as a new therapeutic approach in diffuse large B cell lymphomas with Myc deregulation. **British Journal of Haematology** , 2018, 181, 122–151. (*, equally contributed).
 37. Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, Duval C, Cantarella D, Rinaldi A, Provero P, Di Cunto F, Medico E, Bertoni F, Inghirami G, Piva R. IRF4 mediates the oncogenic effects of STAT3 in Anaplastic Large Cell Lymphomas. **Cancers (Basel)** 2018 Jan 18;10(1). pii: E21. doi: 10.3390/cancers10010021..
 38. Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L. Combining ibrutinib with Chk1 inhibitors synergistically targets mantle cell lymphoma cell lines. **Targeted Oncology** 2018 Apr;13(2):235-245.
 39. Bernasconi E*, Gaudio E*, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. **British Journal of Haematology** 2017; 178(6): 936-948. (*, equally contributed)
 40. Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. **British Journal of Haematology** 2017 doi: 10.1111/bjh.14817. [Epub ahead of print].
 41. Gaudio E*, Paduano F*, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan R.I., Croce C.M., Bertoni F, Alcaro S, Trapasso F. TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. **British Journal of Haematology** 2017 Oct 19. doi: 10.1111/bjh.14989. [Epub ahead of print]: in press (*, equally contributed)
 42. Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. **Nature Medicine** 2017; 23(9): 1046-1054.
 43. Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. **Oncotarget** 2017; 8(5):7598-7613.
 44. Akhmedov M, Kedaigle A, Escalante Ching R, Montemmani R, Bertoni F, Fraenkel E, Kwee I. PCSF: an R-package for Network-Based Interpretation of High-throughput Data. **PLOS Computational Biology** 2017 Jul 31;13(7):e1005694.
 45. Puddinu V, Radice E, Casella S, Thelen S, Dirnhofer S, Bertoni F, Thelen M. ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. **Oncotarget** 2017; doi.org/10.18632/oncotarget.18844
 46. Bujisic B, De Gassart A, Tallant R, Demaria O, Zaffalon L, Chelbi S, Gilliet M, Bertoni F, Martinon F. Impaired IRE1 expression and XBP1 activation is a hallmark of GCB-DLBCL and contributes to tumor growth. **Blood** 2017 Apr 27;129(17):2420-2428.
 47. Leoni C, Montagner S, Rinaldi A, Bertoni F, Polletti S, Balestrieri C, Monticelli S. Dnmt3a restrains mast cell inflammatory responses. **Proceedings of the National Academy of Sciences** 2017; 114(8): E1490-E1499.
 48. Gaudio E*, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, & Bertoni F. Combination of the MEK inhibitor pimasetrib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas. **Annals of Oncology** 2016 Jun;27(6):1123-8. (*, equally contributed).
 49. Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. **Nature Communications** 2016 Dec 12;7:13719.
 50. Boi M*, Todaro M*, Vurchio V, Ning Yang S, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F^, Inghirami G^A. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. **Oncotarget** 2016 Nov 29;7(48):79637-79653. (*, equally contributed; ^, co-senior authors)
 51. Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, & Bertoni F. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. **Oncotarget** 2016 Dec 20;7(51):84675-84687.
 52. Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E, Cvitkovic E, Zucca E, Bertoni F. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong *in vivo* antitumor activity in lymphoma. **Oncotarget** 2016 Sep 6;7(36):58142-58147.
 53. Ganapathi KA, Jobanputra V, Iwamoto F, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, & MM, Bhagat G. The Genetic Landscape of Dural Marginal Zone Lymphomas. **Oncotarget** 2016 Jul 12;7(28):43052-43061.
 54. Spina V*, Hossein Khiabani H* Messina M, Monti S, Cascione L, Brusca A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M,¹ Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D. The genetics of nodal marginal zone lymphoma. **Blood** 2016 Sep 8;128(10):1362-73. (*, equally contributed).
 55. Scarfò I*, Pellegrino E*, Mereu E*, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate A, Barreca A, Domenico Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G^, Piva R^, and the European T-Cell Lymphoma Study Group. Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts. **Blood**, 2016 Jan 14;127(2):221-32. (*, equally contributed; ^, co-senior authors)
 56. Rancoita PMV, Zaffalon M, Zucca E, Bertoni F, de Campos C. Bayesian network data imputation with application to survival tree analysis. **Computational Statistics and Data Analysis**, 2016 January, 93: 373–387.
 57. Arribas AJ*, Rinaldi A*, Mensah AA, Kwee I, Cascione L, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Souliere J, Forconi, F, Zamo' A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F. DNA methylation-profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. **Blood** 2015 Mar 19;125(12):1922-31. (*, equally contributed)

58. Boi M*, Gaudio E*, Bonetti P*, Kwee I, Bernasconi E, Tarantelli, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F. The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs. **Clinical Cancer Research**, 2015 Apr 1;21(7):1628-38. (*, equally contributed)
59. Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Barreca A, Novero D, Gaudio M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal I, Chan WC, Shultz L, Kwee I, Piva R, Wlodarska I, Rabadan R*, Bertoni F*, Inghirami G* (*, co-senior authors). A novel Patient Derived Tumorgraft model with TRAF1-ALK Anaplastic Large Cell Lymphoma translocation. **Leukemia** 2015 Jun;29(6):1390-401
60. Bernasconi E, Gaudio E, Kwee I, Rinaldi A, Cascione L, Tarantelli C, Mensah AA, Stathis A, Zucca E, Vesci L, Giannini G, Bertoni F. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. **British Journal of Haematology** 2015;171(3):378-86.
61. Mensah AA, Kwee I, Gaudio E, Rinaldi A, Ponzoni M, Cascione E, Fossati G, Stathis A, Zucca E, Caprini G, Bertoni F. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of *CDKN1A* expression levels in mediating their anti-tumor response. **Oncotarget** 2015 Mar 10;6(7): 5059-71.
62. Vesci L*, Bernasconi E*, Milazzo FM, De Santis R, Gaudio E, Kwee I, Rinaldi A, Pace S, Carollo V, Giannini G, Bertoni F. Preclinical antitumor activity of ST7612AA1: a novel second generation oral histone deacetylase (HDAC) inhibitor. **Oncotarget** 2015 Mar 20;6(8):5735-48. (*, equally contributed)
63. Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G*, & Carrassa L*. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. **Oncotarget** 2015 Nov 10;6(35):37229-40.
64. Franceschetti S, Conconi A, Aprile Von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia A, Bertoni F, Gaidano G, Cavalli F, Zucca E. Histologic Transformation In Marginal Zone Lymphomas. **Annals of Oncology**, 2015 Nov;26(11):2329-35.
65. Conconi A*, Lobetti-Bodoni C*, Montoto S, Lopez-Guillermo A, Coutinho R, J Matthews J, S Franceschetti S, Bertoni F, Moccia A, Rancoita PMV, Gribben J, Cavalli F, Gaidano G, Lister A, Montserrat E, Ghielmini M, & Zucca E. Life expectancy of young adults with follicular lymphoma. **Annals of Oncology**, 2015 Nov;26(11):2317-22. (*, equally contributed)
66. Chila' R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F*, Damia G*, Carrassa L* (*, co-senior authors). Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for Mantle Cell Lymphoma. **Oncotarget**, 2015 Feb 20;6(5):3394-408.
67. Crescenzo R, Abate F, Lasorsa E, Tabbò F, Gaudio M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni E, Rabadan R*, Inghirami G*, the European T-cell Lymphoma Study Group, T-Cell Project. (*, co-senior authors). Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in Anaplastic Large Cell Lymphoma. **Cancer Cell** 2015 Apr 13;27(4):516-32.
68. Alajati A*, Guccini I*, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Catapano C, Bertoni F, & Alimonti A. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. **Cell Reports** 2015 Apr 28;11(4):564-76. (*, equally contributed)
69. Ferretti E, Di Carlo E, Ognio E, Guarnotta C, Bertoni F, Corcione A, Prigione I, Fraternali-Orcioni G, Ribatti D, Ravetti JL, Ponzoni M, and Pistoia V. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. **Oncolmmunology** 2015 Jun 19;4(10):e1030560.
70. Iacovelli S, Hug E, Bennardo S, Dühren-von Minden M, Rinaldi A, Gobessi S, Suljagic M, Bilbao D, Bolasco G, Eckl-Dorna J, Niederberger V, Laurenti L, Wang H, Cornall RJ, Larke SH, Croce CM, Bertoni F, Jumaa H, and Efremov DG. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. **Blood** 2015 Mar 5;125(10):1578-88.
71. Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Brusca A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal-Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri S, Foà R, Inghirami G, Gaidano G, Rossi D. The *Krüppel-like Factor 2* transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. **Leukemia** 2015 Feb;29(2):503-7.
72. Young Ok C, Chen J, Zijun Y, Xu-Monette ZY, Tzankov A, Ganiraju C, Manyam GC, Ling Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, His ED, Choi WWL, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJM, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Clinical Implications of Phosphorylated STAT3 Expression in de novo Diffuse Large B-cell Lymphoma. **Clinical Cancer Research** 2014, 20(19): 5113-5123.
73. Bouska A, McKeithan T, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Staudt LM, Chan WC. Genome-wide copy number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. **Blood**, 2014 Mar 13;123(11):1681-90.
74. Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Martínez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Díez C, García JF, Fraga M, Sebastián E, Alvéz J, Menárguez J, González-Carrero J, Casado LF, Bayes M, Bertoni F, Gut I, & Piris MA. Whole exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. **Leukemia** 2014 Jun;28(6):1334-40.
75. Mian M, Kwee, Rinaldi A, Ponzoni M, Bhagat G, Rossi D, Arcaini L, Gascoyne RD, Mollejo M, Baldini L, Thieblemont C, Gaidano G, Zucca E, Bertoni F. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. **British Journal of Haematology** 2014 Mar;164(6):896-9.
76. Ronchetti D, Tuana G, Rinaldi A, Agnelli L, Cutrona G, Mosca L, Fabris S, Matis S, Colombo M, Gentile M, Recchia AG, Kwee I, Bertoni F, Morabito F, Ferrarini M, Neri A. Distinct Patterns of Global Promoter Methylation in Early Stage Chronic Lymphocytic Leukemia. **Genes Chromosomes and Cancer**, 2014 Mar; 53(3): 264-73.
77. Monti S, Deambrogi S, Rinaldi A, Bertoni F, Gaidano G, Rossi D. MYC networks mutations in high risk chronic lymphocytic lymphoma. **Hematological Oncology** 2014; 32 (3):155-7.

B) REVIEWS AND EDITORIALS

1. Bertoni F & Stathis A. BET inhibitors for lymphoid malignancies. **Current Opinion in Hematology** 2019 Jul;26(4):273-280. doi: 10.1097/MOH.0000000000000519.
2. Mondello P, Mian M, Bertoni F. Primary central nervous system lymphoma: novel precision therapies. **Critical Reviews in Oncology/Hematology** 2019: *in press*.
3. Stathis A & Bertoni F. BET proteins as targets for anti-cancer treatment. **Cancer Discovery** 2018 Jan;8(1):24-36.
4. Minotti G, Han H, Cattani V, Egorov A, Bertoni F. Pixantrone: novel mode of action and clinical readouts. **Expert Review of Hematology** 2018 Jul; 11(7): 587-598.
5. Paduano F*, Gaudio E*, Mensah AA, Pinton S, Bertoni F, Trapasso F. T-Cell Leukemia/Lymphoma 1 (TCL1): an oncogene regulating multiple signaling pathways. **Frontiers in Oncology** 2018 Aug 13; 8: 317. (*, equally contributed).
6. Bertoni F*, Rossi D* & Zucca E. Recent advances in understanding the biology of marginal zone lymphoma. **F1000Research** 2018, 7(F1000 Faculty Rev):406 (doi: 10.12688/f1000research.13826.1). (*, equally contributed).
7. Bertoni F. Let's give BACH2 a breath of fresh air. **Blood** 2017 Aug 10; 130(6): 696-697.
8. Bertoni F & Stathis A. Staining the target: CD37 expression in lymphomas. **Blood** 2016 Dec 29;128(26):3022-3023.
9. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. **Blood** 2016 Apr 28;127(17):2082-92.
10. Arribas AJ, Bertoni F. Methylation patterns in marginal zone lymphoma. **Best Practice & Research Clinical Haematology** 2016; 30(1): 24-31.
11. Pizzi M, Boi M, Bertoni F, & Inghirami G. Emerging therapies provide new opportunities to reshape the multifaceted interactions between immune system and lymphoma cells. **Leukemia** 2016 Sep;30(9):1805-1815.
12. Cogliatti S, Bargetzi M, Bertoni F, Hitz F, Lohri A, Mey U, Papachristofilou A, Taverna C, Zucca E & Renner C. Diagnosis and treatment of marginal zone lymphoma. **Swiss Medical Weekly** 2016;146 (SUPPL 216): 1S-12S.
13. Testoni M, Young KH, Zucca E, Bertoni F. Genetic lesions in diffuse large B-cell lymphoma. **Annals of Oncology** 2015 26 (6): 1069-1080.
14. Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. **British Journal of Haematology** 2015 Mar;168(6):771-83.
15. Testoni M, Chung EY, Priebe V, & Bertoni F. The transcription factor ETS1 in lymphomas: friend or foe? **Leukemia and Lymphoma** 2015 Jan 14:1-6.
16. Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-Cell Lymphomas. **Clinical Cancer Research** 2014; 20(20): 5207-5216.
17. Boi M, Zucca E, Inghirami G, & Bertoni F. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. **Leukemia and Lymphoma** 2014 Oct 7:1-6.
18. Zucca E, Stathis A, & Bertoni F. How An Expert Approaches It: The Management of Nongastric MALT Lymphomas. **Oncology** 2014; 28 (1): 86-93.
19. Thieblemont C*, Bertoni F*, Copie-Bergman C, Ferreri A, & Ponzoni M. Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT –type. **Seminars in Cancer Biology** 2014 Feb;24:33-42. *, equally contributed.

C) BOOK CHAPTERS

1. Bertoni F. Molecular biology of lymphomas. In: Ghielmini M, Montoto S. (eds) **Lymphoma - Essentials for Clinicians, 2nd edition**. ESMO Press, 2015: 81-84.
2. Bertoni F, Zucca E. Extranodal marginal zone lymphoma of MALT type. In: Ghielmini M, Montoto S. (eds) **Lymphoma - Essentials for Clinicians, 2nd edition**. ESMO Press, 2015: 55-60.
3. Bertoni F, Forconi F, Dal-Bo M, Zucchetto A, Bomben R, Del Poeta G, Gattei V. Molecular Pathology - B-cell chronic lymphocytic leukemia. In: Gelmann E, Sawyers C, Rauscher F III (eds). **"Molecular Oncology: Causes of Cancer and Targets for Treatment"**, Cambridge University Press, 2014: 786-792.
4. Zucca E, Bertoni F. MALT and Other Marginal Zone Lymphomas. In: Marcus R., Sweetenham J.W., Williams M.E. (eds). **"Lymphoma: Pathology, Diagnosis and Treatment (2nd ed.)"**, Cambridge University Press, 2014: 104-120.